文章：

非编码RNA在前列腺癌谱系可塑性中的作用

Role of non-coding RNA in lineage plasticity of prostate cancer 

原文发布日期：2024-11-04 

英文摘要：

The treatment of prostate cancer (PCa) has made great progress in recent years, but treatment resistance always develops and can even lead to fatal disease. Exploring the mechanism of drug resistance is of great significance for improving treatment outcomes and developing biomarkers with predictive value. It is increasingly recognized that mechanism of drug resistance in advanced PCa is related to lineage plasticity and tissue differentiation. Specifically, one of the mechanisms by which castration-resistant prostate cancer (CRPC) cells acquire drug resistance and transform into neuroendocrine prostate cancer (NEPC) cells is lineage plasticity. NEPC is a subtype of PCa that is highly aggressive and lethal, with a median survival of only 7 months. With the development of high-throughput RNA sequencing technology, more and more non-coding RNAs have been identified, which play important roles in different diseases through different mechanisms. Several ncRNAs have shown great potential in PCa lineage plasticity and as biomarkers. In the review, the role of ncRNA in PCa lineage plasticity and its use as biomarkers were reviewed. 

摘要翻译：

近年来，前列腺癌（PCa）的治疗取得了巨大进展，但耐药性始终会发生发展，甚至可能导致致命疾病。探索耐药机制对改善治疗效果和开发具有预测价值的生物标志物具有重要意义。人们日益认识到晚期前列腺癌的耐药机制与谱系可塑性和组织分化有关。具体而言，去势抵抗性前列腺癌（CRPC）细胞获得耐药性并转化为神经内分泌前列腺癌（NEPC）细胞的机制之一就是谱系可塑性。NEPC是一种高度侵袭性和致命性的前列腺癌亚型，中位生存期仅为7个月。随着高通量RNA测序技术的发展，越来越多的非编码RNA被发现，它们通过不同机制在不同疾病中发挥重要作用。若干非编码RNA在前列腺癌谱系可塑性方面展现出巨大潜力，并具有作为生物标志物的价值。本综述阐述了非编码RNA在前列腺癌谱系可塑性中的作用及其作为生物标志物的应用。

原文链接：

Role of non-coding RNA in lineage plasticity of prostate cancer